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Although some patients are initially sensitive to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR
TKIs), resistance invariably develops. Therefore, it’s very important to study the molecular mechanism of this
resistance. In our previous study we found that integrin beta1 can induce EGFR TKIs resistance in non-small cell
lung cancer (NSCLC) cells. Here we analyzed the association of integrin beta1 and c-MET that is a recognized
mechanism of EGFR TKIs resistance in NSCLC to demonstrate the mechanism of integrin beta1 related EGFR TKIs
resistance. We found that the ligands of integrin beta1 and c-MET could synergistically promote cell proliferation
and their inhibitors could synergistically improve the sensitivity to gfitinib, increase apoptosis, and inhibit the
downstream signal transduction: focal adhesion kinase (FAK) and AKT. On the other hand, ligand-dependent
activation of integrin beta1 could induce EGFR TKIs resistance through activating c-MET and its downstream signals.
Thus, it can be concluded that there is crosstalk between integrin beta1 and c-MET and integrin beta1 mediates
EGFR TKI resistance associating with c-MET signaling pathway in non-small cell lung cancer.
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The EGFR inhibitor gefitinib has been used as a single
agent in NSCLC, but overall, the resistance remains a
major problem clinicians encountered. Our previous
result has shown that integrin beta1 overexpression
associates with EGFR TKI resistance in PC9/AB2 cells
[1]. In this study we further investigated the mechanism
of integrin beta1-related EGFR TKI resistance.
Integrins and are formed by α and β integrin subunits.
There are at least 24 known heterodimers formed by 18
α and eight β subunits. Natural integrin ligands include
important components of the extracellular matrix
(ECM). Beta1 subunit of integrin is an adhesion mol-
ecule involved in cell survival and cancer resistance to
radiotherapy and chemotherapy [2-4], sharing common
downstream signaling elements with EGFR, such as the* Correspondence: caicunzhou@yahoo.com.cn
2Cancer Institute, Department of Oncology, Shanghai Pulmonary Hospital,
Tongji University, Medical School, 507 Zhengmin Road, Shanghai 200433,
China
Full list of author information is available at the end of the article
© 2013 Ju and Zhou; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orphosphatidylinositol 3-kinase/AKT and extracellular
signal-regulated kinase-1/2 (ERK1/2) pathways [5-9].
The c-MET receptor is a 190-kD disulfide linked α-β
heterodimer [10]. and expressed in 60%–80% of NSCLC
[11]. Unlike EGFR, the only known natural ligand for
c-MET is hepatocyte growth factor (HGF, also known
as scatter factor). Activation of c-MET can lead
to proliferation, increased survival, altered motility,
enhanced invasion into extracellular matrix, and more
rapid formation of tubules [12]. On activation by
autophosphorylation, c-MET can activate its multiple
downstream signal transduction intermediates. Novel
small molecule inhibitors of c-MET, SU11274 [13] and
PHA-665752 [14] have shown to inhibit the phosphoryl-
ation of c-MET and the proliferation of cells in vitro.
In recent years, c-MET also has been found to be an
independent biomarker of EGFR TKI resistance and
about 21% acquired EGFR TKI resistance is caused by
overexpression of c-MET [15]. Another research found
that through promoting MET-integrin association,
HGF-FN and HGF-VN complexes coordinated and
enhanced endothelial cell migration through activationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mechanism [16]. There is also an important crosstalk
between c-MET and the integrin beta1 in mast cell:
stimulation through c-MET and the α2β1 integrin
resulted in crosstalk between the two receptors,
resulting in the activation of the mast cell leading to
release of the pro-inflammatory cytokine, IL-6 [17].
Therefore, the crosstalk between integrin beta1 and
c-MET may be also related with EGFR TKI resistance.
In present study, we investigated the relationship
between integrin beta1 and c-MET in EGFR TKI resist-
ance to explore the mechanism of EGFR TKI resistance
in non-small cell lung cancer.
Materials and methods
Ethics approval
All experiments were performed with the approved of the
Tongji University Institutional Care and Use Committee
(IACUC).
Reagents and antibodies
Human phospho-ERK antibody and human phospho-FAK
antibody were purchased from Animal BioWorld Tech-
nology (Dublin, OH); human c-MET antibody, human
phospho-AKT antibody, human phospho-c-MET antibody
and human phospho-EGFR antibody were purchased
from Cell Signaling Technology (Beverly, MA); β-actin
antibody was purchased from ABGENT (San Diego, CA);
human integrin beta1/CD29 antibody was purchased
from R&D Systems (Minneapolis, MN); IRDyeTM 800
Conjugated Affinity Purified Anti-mouse/rabbit Antibody
was purchased from Rockland (Gilbertsville, PA).
Cell lines and cell culture
Human NSCLC cell line PC9 (harboring EGFR exon 19
deletion) was provided by Cancer Institute of Medical
School, Tongji University, China [the original PC-9 cells
were purchased from Immuno-Biological Laborato-
ries (Takasaki, Gunma, Japan). The gefitinib-resistant
NSCLC subline PC9/AB2 was induced from PC9 cells
according to the method in the literature [18] and was
continuously subcultured with 2 μmol/L of gefitinib for
additional 6 months. The resistance of PC9/AB2 cells to
gefitinib has been proved to maintain for at least one
year in the medium without gefitinib and there is no
T790M in PC9/AB2 [1]. PC9/AB2 cells were stablely
transfected with integrin beta1-siRNA plasmid and
scrambled siRNA plasmid and were named by AB2/17-
2 and AB2/N respectively; The integrin beta1 cDNA
plasmid and the vacant vector were stablely transfected
into PC9 cells and were named by PC9/D6, PC9/PCD
respectively [1]. All these cells were cultured at 37°C
with 5% CO2 in Dulbecco’s modified Eagle’s medium(DMEM) supplemented with 10% fetal bovine serum
(FBS), 100 U/ml penicillin and 100 mg/ml streptomycin.
Western blot assay
Cells were washed twice with ice-cold PBS and lysed in
0.1 ml of lysis buffer on ice for 30 min. Insoluble debris
was removed by centrifuging at 13,000 rpm for 15 min
at 4°C. Electrophoresis and blotting procedures were
done according to methods described previously. Primary
antibodies against human integrin beta1/CD29, human c-
MET antibody, human phospho-EGFR and phospho-AKT,
phospho-ERK1/2 and phospho-FAK were used according
to the manufacturer’s instructions. Blotting quantification
was done with an OdysseyW Infrared Imaging system
(LI-COR, USA).
Fibronectin (FN) stimulate growth
96-well plates were coated with or without fibronectin
(FN) 20 μg/ml 100 μl. PC9, PC9/AB2 (5000 /well) were
plated in 96-well plates. After 24 h, the wells were treated
with or without HGF 50 ng/ml, or treated with both of
them in medium with 10% FBS. After 24 h, viable cells
were detected by MTT assays and cell viability was plotted
as a mean ± SD of three independent experiments.
Percentage of cell viability was determined relative to the
control that had no additional growth factors [19].
Cell proliferation assay
The cells (5 × 103/well) were seeded into 96-well plate
in quadruplicate and were exposed to various con-
centrations of gefitinib. After 72 hours, 20 μl of 3-
(4,5-diMEThylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) solution (5 mg/ml) was added to each well and
incubated. After 4 hours, crystalline formation was
dissolved with Dimethyl sulfoxide (DMSO) and the ab-
sorbance at 530 nm was read using the microplate-reader
for ELISA MK-2 Labsystems Dragon. The IC50 was
defined as the concentration needed for a 50% reduction
of the absorbance based on the survival curves. Percent
survival was calculated as: (mean absorbance of the rep-
licate wells containing drugs_mean absorbance of the
replicate background wells) / (mean absorbance of the
replicate drug-free wells_mean absorbance of the repli-
cate background wells). The test was performed independ-
ently 3 times. All results were derived from quadruplicate
experiments yielding almost similar results.
Apoptosis assay
Transferase-mediated deoxyuridine triphosphate nick-
end labeling (TUNEL) Kit (Promega, USA) were used
for apoptosis assay. In TUNEL assay, cells were seeded
in 24-well plates and exposed to gefitinib (5 or 15 μmol/L)
for another 48 h. Then, apoptosis was assessed by
the TUNEL assay kit (GENMED, China) following the
Ju and Zhou Cancer Cell International 2013, 13:15 Page 3 of 7
http://www.cancerci.com/content/13/1/15manufacturer’s protocol. Apoptotic index (AI) (%) was
calculated by the formula: positive staining cells/tumor cells
number × 100%.
Statistical analyses
Values were expressed as mean ± SD. Statistical analysis
was done by independent-samples t test. Differences
were considered to be statistically significant if P < 0.05.
Results
Integrin beta1 and c-MET co-expressed in PC9 and PC9/
AB2 cell lines
The expression of integrin beta1 and c-MET were
determined by western blot. Integrin beta1 and c-MET
were both expressed in the PC9 and PC9/AB2. Integrin
beta1 expression was higher in PC9/AB2 than in PC9,
and c-MET expression was comparable in the two cell
lines (Figure 1A).
Fibronectin (FN) and HGF effect on the growth of PC9
and PC9/AB2 cell lines
FN is the ligand of integrin beta1 and HGF is the ligand of
c-MET. The effects of FN and HGF on cell growth were
studied by treating cells with 20 μg/ml FN or 50 ng/ml of
HGF alone or in combination, and cell proliferation was
determined by MTT as aforementioned. In PC9 and PC9/
AB2 cells, a synergistic proliferative effect was observed
with a combination of FN and HGF (Figure 1B).
A synergistic effect can be defined as an effect that is
more than the additive effect of FN and HGF alone.
Combination Index (CI) = (D) 1/ (D m) 1 + (D) 2 /(D m)
2 . Where (D) 1 and (D) 2 are the doses of chemicals 1
and 2 that in combination produce some specified effect
(i. e. 50% inhibition of luminescence) and (D m) 1 and
(D m) 2 are the doses of the chemicals that when
applied singly also have the same effect (50% inhibition
of luminescence).
These results indicated that there was a synergistic
proliferative effect of both ligands combined. Maybe be-
cause the level of integrin beta1 in PC9/AB2 cells is higher
than that in PC9 cells, the synergistic effect of HGF and FN
in PC9/AB2 cells is more evident than in PC9 cells. These
results could be due to potential crosstalk between integrin
beta1 and c-MET signaling pathways.
Combination of integrin beta1-target siRNA and c-MET
kinase inhibitor SU11274 synergized to inhibit
proliferation of PC9/AB2 NSCLC cell line
Since the synergistic proliferative effect of HGF and FN
has been observed, we want to know whether the syner-
gistic inhibition to cell growth can be found when we
combined integrin beta1 siRNA with c-MET kinase
inhibitor SU11274. The IC50 for each treatment was
determined by MTT assay. The results shown that theIC50 for gefitinib alone and the combination of
SU11274 and gefitinib were (24.2 ± 5.45) μmol/L and
(7.34 ± 2.84) μmol/L in PC9/AB2 cells, respectively.
Interestingly, a synergistic effect of gefitinib on inhib-
ition of cell proliferation was seen in the presence of
same dose of SU11274 in integrin beta1-inhibited AB2/
17-2 cells. The IC50 for gefitinib alone in AB2/17-2 cells
was (1.9 ± 1.28) μmol/L, however the IC50 was (0.26 ±
0.15) μmol/L in the presence of same dose of SU11274
(Figure 1C). So, to inhibit the cells growth by 50%, we
need 30% or 8% of original gefitinib concentration
respectively in presence of SU11274 or integrin beta1-
siRNA only. But we need only 1% of original gefitinib
concentration when SU11274 and integrin beta1-target
siRNA were combined. It suggested that combined
inhibition of integrin beta1 and c-MET could improve
effect of gefitinib in PC9/AB2 NSCLC cell line
synergistically.
Combination of integrin beta1-target siRNA and c-MET
kinase inhibitor SU11274 induced apoptosis in a
synergistic fashion
TUNEL assay was performed to examine apoptosis. As
shown in Figure 1D, the apoptosis rates of PC9/AB2 cells
treated with SU11274 or gefitinib alone or in combination
were (5.38 ± 1.94)%, (9.33 ± 0.98)%, and (15.48 ± 2.32)%
respectively. And the apoptosis rates of integrin beta1-
inhibited AB2/17-2 cells treated with SU11274 or gefitinib
alone or in combination were (7.8 ± 1.56)%, (26.68 ±
3.10)%, and (49.72 ± 6.82)% respectively. It suggested that
the combination of integrin beta1-target siRNA and
SU11274 could increase apoptosis induced by gefitinib in
PC9/AB2 cell line in a synergistic fashion.
Combination of integrin beta1-target siRNA and c-MET
kinase inhibitor SU11274 reduced phosphorylation of
EGFR and its downstream signals synergistically
After 30min of treatment with EGF, we investigated the
phosphorylation level of EGFR and several of its down-
stream signaling intermediates (Figure 1E). The synergistic
reduction of phosphorylation levels were observed in
EGFR, AKT and FAK. Phosphorylation of ERK decreased
significantly with c-MET inhibition but not with integrin
beta1 inhibition. The results indicated that there was a
crosstalk between c-MET and integrin beta1, and activation
of AKTand FAK were very important for this crosstalk.
Activation of integrin beta1 by FN increased gefitinib
resistance
In our previous research, we found that FN could increase
cell adhesion1, so we investigated whether or not activa-
tion of integrin beta1 by FN could improve survival
and increase gefitinib resistance. The IC50 of gefitinib in
PC9 and PC9/D6 cells were (0.042 ± 0.01) μmol/L and
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Figure 1 The crosstalk between integrin beta1 and c-MET. A Western blot analysis showed that integrin beta1 and c-Met co-expressed in
PC9 and PC9/AB2 cells. B MTT analysis of proliferative effect of PC9 and PC9/AB2 cells treated with FN and HGF alone or in combination showed
a synergistic proliferative effect when FN and HGF combined. C MTT analysis showed that combination of integrin beta1-target siRNA and c-MET
kinase inhibitor SU11274 synergized to inhibit proliferation of PC9/AB2 NSCLC cell line. D TUNEL analysis showed that inhibition of c-Met and
integrin beta1 concurrently induced apoptosis synergistically. E Western blot analysis showed that phosphorylation of c-Met, EGFR, FAK and AKT
were reduced synergistically when c-Met and integrin beta1 were inhibited in PC9/AB2 cells. *G means treatment of gefitinib and P
means phosphorylation.
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were (0.08 ± 0.03) μmol/L and (17.50 ± 4.15) μmol/L in
PC9 and PC9/D6 cells when co-treated with FN, respect-
ively (Figure 2A). These data suggested that activation of
integrin beta1 by FN could induce gefitinib resistance.Activation of integrin beta1 by FN decreased gefitinib-
induced apoptosis
To further confirm that the activation of integrin beta1 by
FN have some effect on EGFR TKI resistance, we detected
the apoptosis of PC9, PC9/D6 cells treated with gefitinib
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1.80) %, (0.95 ± 2.13) % in PC9 and PC9/D6 cells, respect-
ively. Their apoptosis rates were (49.75 ± 8.60) %, (12.87 ±
1.53) % when treated with gefitinib. However, they were
(38.09 ± 7.84) %, (4.20 ± 4.29) % when treated with FN and
gefitinib, respectively (Figure 2B). The apoptosis were both
decreased after treated with FN, but that of integrin beta1-
overexpressed PC9/D6 cells descended markedly.
Ligand-dependent activation of integrin beta1 induced
c-MET and its downstream signals activation
After activation of integrin beta1 by FN, phosphoryl-
ation of c-MET, FAK, AKT, and ERK were all increased
significantly. It suggested that ligand-dependent activa-
tion of integrin beta1 induced c-MET activation and
phosphorylation of FAK, AKT, and ERK were related to
this effect. So we concluded that ligand-dependent

























































Figure 2 Overexpression and activation of integrin beta1 induce gefi
showed that activation of integrin beta1 by FN could induce gefitinib resis
were decreased markedly after treated with FN. C Western blot analysis sho
phosphorylation of c-Met, FAK, and AKT in PC9/D6 cells. D Overexpression
phosphorylation of c-MET and its downstream signals: FAK, AKT.resistance through increasing phosphorylation of c-
MET and of its downstream signaling pathways: FAK,
AKT and ERK (Figure 2C).
Discussion
In this work, we demonstrate that there is crosstalk
between integrin beta1 and c-MET and this crosstalk
regulates EGFR TKIs resistance in NSCLC. We provide
evidence that integrin beta1/MET crosstalk is a key fac-
tor of EGFR TKIs resistance, thus rendering integrin
beta1/c-MET a suitable double-target for adjuvant ther-
apy in combination with anti-EGFR agents currently
used in clinic.
Although the patients with mutant EGFR display
dramatic response to EGFR TKIs, duration of response
is typically only 9 to 10 months and then most patients
eventually acquire resistance to the agents [20,21],
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T790M mutation and c-MET gene amplification have
been found to be related to acquired resistance to EGFR
TKIs in NSCLC [22-24]. Except for the above two
mechanisms, others that account for the remaining
about 30% of acquired resistance are still unclear. Some
papers showed that integrin beta1 signaling has been
implicated in the progression and metastasis of various
cancers, and shown to facilitate resistance to radiation
therapy [25] and drug resistance [26]. Moreover, our
previous research had confirmed that integrin beta1 was
responsible for EGFR TKI resistance.
Integrin beta1, that associates with the adhesion and
migration capability of tumor cells and has a key role in
the growth and metastasis of tumors, is an important
molecular of the adhesion-mediated drug resistance
[27-29]. The FN receptor (α5β1-integrin) binds to
fibronectin to anchor cells and activates non receptor
tyrosine kinases, FAK and Src, which play an important
role in tumorigenesis by promoting the proliferation
and invasion of cancer and endothelial cells [30,31]. In
our previous research, we have established the cell lines
with stable down- and up- expression of integrin beta1
by transfecting siRNA or integrin beta1 cDNA plasmid
into PC9/AB2 cells or PC9 cells, respectively. After
down-regulation of integrin beta1, PC9/AB2 cells par-
tially restored sensitivity to gefitinib while up-regulation
of integrin beta1 led to resistance of PC9 cells to
gefitinib. Expression level of integrin beta1 was nega-
tively correlated with gefitinib sensitivity in these two
cell lines. These data identified that integrin beta1 is an
important factor of EGFR TKIs resistance. Morello also
found that the integrin beta1-silenced cells showed a
defective activation of the EGFR signaling cascade,
leading to decreased in vitro proliferation, enhanced
sensitivity to gefitinib, impaired migration and invasive
behavior [5].
Our results showed that both integrin beta1 and c-MET
were expressed in these cell lines, and their ligands can
enhance cell proliferation synergistically. Importantly,
inhibition of both receptors led to growth inhibition and
apoptosis, and down-regulation of phosphorylation of
molecules in their downstream signal transduction (such
as the AKT, FAK pathways) in a synergistic fashion.
Ligand-dependent activation of integrin beta1 induced c-
MET and it’s downstream signals activation (FAK, and
AKT). Mitra et al. also reported that inhibition of
α(5)β(1)-integrin decreased the phosphorylation of c-Met,
FAK and Src, both in vitro and in vivo. Activation of c-
Met by its ligand, HGF/SF, or overexpression of a consti-
tutively active FAK in HeyA8 cells could overcome the
effect of α(5)β(1)-integrin inhibition on tumor cell
invasion, indicating that α(5)β(1)-integrin is upstream of
c-Met, Src and FAK. Inhibition of α(5)β(1)-integrin oncancer cells in two xenograft models of ovarian cancer
metastasis resulted in a significant decrease of tumor
burden, which was independent of the effect of α(5)β(1)-
integrin on angiogenesis [32]. These data shows that there
is a crosstalk between integrin beta1 and c-MET signaling
pathways, and it reaches consensus with Beviglia’s results
that the two signaling pathways, integrin/ECM and
c-MET/HGF, cooperate synergistically to induce FAK
activation in an adhesion-dependent manner, leading to
enhanced cell adhesion and motility [33].
In conclusion, we identified that the crosstalk between
integrin beta1 and c-MET via AKT and FAK signaling
pathways is very important in EGFR TKI resistance. Our
findings identified a new molecular mechanism of EGFR
TKIs resistance, which will provide an effective thera-
peutic intervention of EGFR TKIs resistance.
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